A Randomised, double-blind, phase II study to evaluate the safety and efficacy of Anti-TGF-beta-1-monoclonal-antibody in patients with Diabetic Nephropathy

Trial Profile

A Randomised, double-blind, phase II study to evaluate the safety and efficacy of Anti-TGF-beta-1-monoclonal-antibody in patients with Diabetic Nephropathy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top